Takeda Pharmaceutical (NYSE:TAK) Upgraded to “Strong-Buy” at Zacks Research

Takeda Pharmaceutical (NYSE:TAK) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Wednesday, Zacks reports.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Price Performance

TAK stock opened at $18.71 on Wednesday. The firm has a market cap of $59.95 billion, a price-to-earnings ratio of 55.03 and a beta of -0.07. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $18.90. The company’s fifty day simple moving average is $17.26 and its 200 day simple moving average is $17.20.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.54. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The business had revenue of $7.50 billion for the quarter, compared to analysts’ expectations of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, analysts expect that Takeda Pharmaceutical will post 1.54 earnings per share for the current year.

Insider Transactions at Takeda Pharmaceutical

In other news, insider Deidre Greenway sold 12,980 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $18.11, for a total value of $235,067.80. Following the completion of the sale, the insider directly owned 40,049 shares in the company, valued at $725,287.39. This trade represents a 24.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Andrew Plump sold 19,651 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $18.49, for a total value of $363,346.99. Following the completion of the sale, the insider directly owned 261,656 shares of the company’s stock, valued at $4,838,019.44. The trade was a 6.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 476,731 shares of company stock valued at $8,192,525. 0.04% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its stake in shares of Takeda Pharmaceutical by 11.0% in the first quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock valued at $6,558,000 after buying an additional 43,706 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Takeda Pharmaceutical by 43.6% during the first quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock worth $2,911,000 after acquiring an additional 59,442 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after acquiring an additional 692,404 shares in the last quarter. Focus Partners Wealth raised its holdings in shares of Takeda Pharmaceutical by 4.1% in the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock worth $1,230,000 after acquiring an additional 3,239 shares during the last quarter. Finally, Sivia Capital Partners LLC acquired a new stake in shares of Takeda Pharmaceutical in the 2nd quarter worth about $351,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.